Loading clinical trials...
Loading clinical trials...
A Phase 2, Open-Label, Repeat Dose, Multi-Center Study to Evaluate the Safety of RT001 Topical Gel for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults
This study's objective is to evaluate if RT001 is safe and well-tolerated following two (2) sequential applications.
Revance is conducting this Phase 2 clinical study to establish the safety of two (2) sequential doses of RT001 Topical Gel at Baseline (Day 0) and Week 4 for the treatment of moderate to severe LCLs at rest.
Age
18 - 65 years
Sex
ALL
Healthy Volunteers
Yes
Total Skin & Beauty Dermatology Center, PC
Birmingham, Alabama, United States
Therapeutics Clinical Research
San Diego, California, United States
Skin Specialists, PC
Omaha, Nebraska, United States
Start Date
May 1, 2010
Primary Completion Date
July 1, 2010
Completion Date
July 1, 2010
Last Updated
January 17, 2014
40
ACTUAL participants
RT001
DRUG
Lead Sponsor
Revance Therapeutics, Inc.
NCT04818203
NCT06657365
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT04985916